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Background: Structured Product Labeling (SPL) is a document markup standard approved by Health Level Seven
(HL7) and adopted by United States Food and Drug Administration (FDA) as a mechanism for exchanging drug
product information. The SPL drug labels contain rich information about FDA approved clinical drugs. However, the
lack of linkage to standard drug ontologies hinders their meaningful use. NDF-RT (National Drug File Reference
Terminology) and NLM RxNorm as standard drug ontology were used to standardize and profile the product labels.
Methods: In this paper, we present a framework that intends to map SPL drug labels with existing drug ontologies:
NDF-RT and RxNorm. We also applied existing categorical annotations from the drug ontologies to classify SPL drug
labels into corresponding classes. We established the classification and relevant linkage for SPL drug labels using
the following three approaches. First, we retrieved NDF-RT categorical information from the External Pharmacologic
Class (EPC) indexing SPLs. Second, we used the RxNorm and NDF-RT mappings to classify and link SPLs with
NDF-RT categories. Third, we profiled SPLs using RxNorm term type information. In the implementation process, we
employed a Semantic Web technology framework, in which we stored the data sets from NDF-RT and SPLs into a
RDF triple store, and executed SPARQL queries to retrieve data from customized SPARQL endpoints. Meanwhile, we
imported RxNorm data into MySQL relational database.
Results: In total, 96.0% SPL drug labels were mapped with NDF-RT categories whereas 97.0% SPL drug labels are
linked to RxNorm codes. We found that the majority of SPL drug labels are mapped to chemical ingredient
concepts in both drug ontologies whereas a relatively small portion of SPL drug labels are mapped to clinical drug
concepts.
Conclusions: The profiling outcomes produced by this study would provide useful insights on meaningful use of
FDA SPL drug labels in clinical applications through standard drug ontologies such as NDF-RT and RxNorm.Introduction
Structured Product Labeling (SPL) [1] encodes very rich
clinical drug knowledge, such as dosage, strength, usage of
drug, etc. The importance of this resource is widely recog-
nized, and it has been utilized in multiple studies [2,3] to
support clinical and translational research use cases. For
example, the relationships between genes, diseases, drugs,
and adverse events available from SPL drug lavels can assist
clinicians to improve the safety and effectiveness of treat-
ments, and help translational researchers to design novel
bioinformatics algorithms. However, the drug information/
knowledge written into SPL drug labels is currently in
unstructured free text instead of structured codified* Correspondence: zhu.qian@mayo.edu
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the original work is properly cited.information, which poses significant challenges to compu-
tational analysis of the knowledge, and hinders the integra-
tion of SPL drug labels with other existing knowledge
bases. Actually, this is a common scenario occurring in the
biomedical domain, where dozens of public resources
involve laborious processes to manually annotate data. This
is mostly because they are using heterogeneous code
systems to represent their data. Hence, data normalization
and building all possible linkages among these data sets will
make data interoperation and integration feasible.
Semantic Web Technology (SWT) [4] can be useful to
provide a scalable framework for facilitating semantic data
integration of heterogeneous resources and enabling
semantic sharing through the standard query services. It
has been widely used in biomedical domains to formalize
and model medical and biological systems [5-7]. In thestributed under the terms of the Creative Commons Attribution License (http://
permits unrestricted use, distribution, and reproduction in any medium, provided
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implementation step.
The objective of the present study is to map SPL drug
labels into two major standard drug ontologies: the Veter-
ans Administration’s (VA) National Drug File Reference
Terminology (NDF-RT) [8] and the National Library of
Medicine’s (NLM) RxNorm [9]. Our investigation was
guided by answering the following research questions: (1)
how SPL drug labels are covered and connected by
RxNorm and NDF-RT; (2) how to utilize RxNorm/
NDF-RT drug resources to map SPL drug labels from the
drug class and clinical drug perspective; (3) how to explore
the mapping results to build a drug /drug class network; (4)
how to leverage Semantic Web technology to accomplish
the implementation task.
The paper is organized into the following sections. First,
we introduce background information for SPL, NDF-RT,
RxNorm and Semantic Web technology in the Background
section; Second, in the Methods section, we introduce three
main parallel approaches on SPL drug label profiling; Third,
we illustrate our results generated from each step in the
Results section, and then followed by Discussion and
Conclusion.
Background
Structured Product Labeling (SPL)
Structured Product Labeling (SPL) is a document markup
standard approved by Health Level Seven (HL7) [10] and
adopted by FDA as a mechanism for exchanging product
information. SPL defines the human readable label docu-
ments that contain structured content of labeling (all text,
tables and figures) for a product, along with additional
machine readable information (i.e., drug listing data ele-
ments including information about the product and the
packaging). SPLs for all drug products marketed in the
United States are available for download from the National
Library of Medicine's DailyMed website [11] and they were
being used in this study.
National Drug File Reference Terminology (NDF-RT)
NDF-RT [8] is used for modeling drug characteristics
including ingredients, chemical structure, dose form,
physiologic effect, mechanism of action, pharmacokinetics,
and related diseases.
In support of SPL initiative, a non-hierarchical collection
of External Pharmacologic Class (EPC) concepts has been
added to NDF-RT in parallel and analogous with the VA
Drug Classification hierarchy. These concepts are distin-
guished by an “[EPC]” tag suffixed to their preferred names.
Role relationships describing and defining concepts accord-
ing to their relationships with other concepts, originating
from these EPC concepts target concepts from the NDF-
RT Mechanism of Action (MoA), Physiologic Effect (PE),
and Chemical Ingredient (CI) hierarchies that are selectedby the FDA to index their EPC for SPL purposes [12]. The
content model of NDF-RT is shown in Figure 1. Three
kinds of drug concepts are involved in this study,
“VA Product”, “Chemical Ingredient” and “EPC”, of which
“VA Product”, and “Chemical Ingredient” are relevant to
“Clinical Drug”, “Generic Ingredient or Combination” and
“EPC” is analogous with the “VA Drug Classification”
respectively.
RxNorm
RxNorm [9] provides normalized names for clinical drugs
and links its names to many of the drug vocabularies
commonly used. RxNorm reflects and preserves the mean-
ings, concept names, and relationships from these different
copyright holders, such as SPL, NDF-RT, MeSH, and etc.
The “SAB” code is defined by RxNorm to differentiate the
different sources aggregated into RxNorm. For example,
“MTHSPL” indicates that the corresponding concept is
absorbed from SPL and “NDFRT” indicating the source
from NDF-RT. These two sources were used in this study.
RxNorm defines term type “TTY” to indicate the role an
atom plays in its source. The term types are assigned based
on source documentation or NLM understanding of the
source. Table 1 shows a list of term types “TTYs” used in
this study with their names and descriptions, and the
relationships among these term types are shown in
Figure 2.
Semantic web technology
Resource Description Framework (RDF) [14], a W3C
recommendation, is a directed, labeled graph data format
for representing information in the Web. SPARQL is a
query language for RDF graphs [15]. RDF triple store is a
database for the storage and retrieval of RDF metadata,
ideally through standard SPARQL query language. Web
Ontology Language (OWL) is a standard ontology language
for the Semantic Web [16]. NDF-RT and EPC indexing
SPL data used in this study are stored in a RDF triple store
and by executing SPARQL queries to retrieve the desirable
information. With the advance of SWT, linked data has
been developed to describe a method of publishing struc-




In total, 1,247 EPC indexing SPLs in XML format were
downloaded from NLM DailyMed website [11] as of April
12, 2012. An example of the EPC indexing SPL is shown in
Figure 3. Each SPL labelled by setId (SPL unique identifier)
is corresponding to one or multiple EPC classes, which
mapped to NDF-RT concepts by role relationships. Totally
three role relationships were identified from EPC indexing
Figure 1 NDF-RT content model (source from U.S. Department of Veterans Affairs. NDF-RT Documentation April 2012 Version).
Zhu et al. Journal of Biomedical Semantics 2012, 3:16 Page 3 of 10
http://www.jbiomedsem.com/content/3/1/16SPL files: “PE” standing for physiologic effect; “MoA” stand-
ing for mechanism of action; and “Chemical/Ingredient”.RxNorm
In this study, we used the following two files downloaded
from RxNorm in April 9, 2012: 1) RXNCONSO.RRF. The
file includes all connections (965,968 in total) with different
source vocabularies. We used the data from two sources
labeled as “MTHSPL” (the source from SPL) and “NDFRT”
(the source from NDF-RT) in this study; 2) RXNSAT.RRF.
The file includes all source vocabulary attributes that do
not fit into other categories. We used the file to search for
the information about drug categories and connections
among RxNorm, NDF-RT and SPL. There are 6,221,513
entries included in this file. The data from both of these
two files were loaded into a local MySQL database.Methods
System architecture
There are four primary modules in the system, comprising
1) a data transformation module; 2) a data persistenceTable 1 A list of RxNorm term types “TTYs” with names and d
TTY Name
SBD Semantic Branded Drug Ing
SCD Semantic Clinical Drug
IN Ingredients A compound o
PIN Precise Ingredient A specified form
BPCK Brand Name Pack {# (Ingredient Strength
GPCK Generic Pack {# (Ingredient + Stren
BN Brand Name A proprietary name
MIN Multiple Ingredients Two or more ingredients
SY Synonym
TMSY Tall Man Lettering Synonym Tall Man Lettering synonymmodule; 3) a SPL profiling module, in which SPL drug
labels are profiled by EPC, NDF-RT and RxNorm; 4) a
standardized drug/drug class network module. Figure 4
shows system architecture of the four modules.
For the data transformation module, data reformatting
steps were performed for EPC indexing SPL, NDF-RT and
RxNorm individually before loading the data into RDF tripe
store and MySQL database since they are in different data
formats: SPL in XML format, NDF-RT available in OWL,
and RxNorm in the UMLS Rich Representation Format
(RRF). A XML2RDF sub module [17] takes input rendered
in the XML format, and outputs result in the RDF format
through a transparent transformation service. NDF-RT in
OWL was loaded into RDF store directly. RxNorm provides
MySQL script for loading the data into MySQL database
easily.
For the persistence module, we implemented an open
source RDF store “4Store” that is developed by Garlik [18]
and used the RDF store to host the SPL and NDF-RT data.
After loading RDF triples into the RDF store, we implemen-
ted a SPARQL endpoint providing standard SPARQL query
service against the RDF store.escriptions (Source from RxNorm Documentation [13])
Description
redient + Strength + Dose Form + Brand Name
Ingredient + Strength + Dose Form
r moiety that gives the drug its distinctive clinical properties.
of the ingredient that may or may not be clinically active.
Dose Form) / # (Ingredient Strength Dose Form)} Pack [Brand Name]
gth + Dose Form) / # (Ingredient + Strength + Dose Form)} Pack
for a family of products containing a specific active ingredient.
appearing together in a single drug preparation, created from SCDF.
Synonym of another TTY, given for clarity.
of another TTY, given to distinguish between commonly confused drugs.
Figure 2 RxNorm term types relationships (Source from: Nelson SJ, Normalized names for clinical drugs: RxNorm at 6 years.
JAMIA, 2011).
Figure 3 An example of EPC indexing SPL label.
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Figure 4 A diagram illustrating our system architecture.
Figure 5 A SPARQL query for extracting EPC classes and NDF-
RT concepts with their role relationships.
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porated SPL profiling results with our previous standar-
dized drug work [19]. We explored to use Cytoscape [20]
as a general platform for complex network analysis and
visualization.
Profiling by EPC classes
An EPC indexing SPL label is corresponding to one or
multiple EPC classes and is also corresponding to one to
multiple NDF-RT concepts via the following role relation-
ships: “has_Chemical_Structure”, “has_MoA” or “has_PE”.
For example, an EPC indexing SPL label, “BACILLUS
CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTI-
GEN” is mapped to two EPC classes. The first EPC class is
“Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]”,
which is further mapped to “Actively Acquired Immunity
[PE]”, “Vaccines, Attenuated [Chemical/Ingredient]”, and
“BCG Vaccine [Chemical/Ingredient]”; and the second EPC
class is “Live Attenuated Intravesical Bacillus Calmette-
Guerin Vaccine [EPC]”, which is further mapped to
“Increased Macrophage Proliferation [PE]”, “Increased
Immunologically Active Molecule Activity [PE]”, “Vaccines,
Attenuated [Chemical/Ingredient]”, and “BCG Vaccine
[Chemical/Ingredient]”.
The EPC indexing SPL were stored in a RDF triple store.
We executed a SPARQL query (as shown in Figure 5)
against the triple store and extracted setId (unique identifier
of SPL), NUI (unique identifier of NDF-RT), and the rele-
vant role relationships for each EPC indexing SPL. The out-
come of this query is a list of setIds and relevant NDF-RT
concepts with NUIs and display names. Category infor-
mation is embedded in the display name, such as
“Androgen Receptor Inhibitor [EPC]” indicates “Androgen
Receptor Inhibitor” is an EPC class, and “Aminoglycosides
[Chemical/Ingredient]” indicates “Aminoglycosides” is a
chemical ingredient.
Profiling by RxNorm and NDF-RT
The objective of this step was to use existing annotations
from RxNorm to categorize SPL drug labels, and to makeconnections between SPL and RxNorm/NDF-RT. As
RxNorm data (RXNCONSO and RXNSAT) were pre-
loaded in a MySQL database, we executed SQL queries to
extract data from two RxNorm integrated resources: SPL
and NDF-RT, which are differentiated by individual SAB
labels.
For the source SPL (i.e., “SAB = MTHSPL”), we extracted
concept names along with “TTY” (term type) as described
in the Materials section, and RxCUIs (RxNorm unique
identifier) from the RXNCONSO table. To establish
linkages between SPL and RxNorm, we searched the
RXNSAT table for a list of setIds with a given RxCUI. It is
worthy to note that one RxCUI can correspond to multiple
SPLs due to different product labellers. Figure 6 shows the
workflow of the data extraction in this step.
For the source NDF-RT (i.e., “SAB = NDFRT”), SQL
queries were executed to extract concept names along
with NUIs and preferred names. Each preferred name
includes role relationships information. For example, an
entry with [RxCUI = “4278”] corresponds to the [NUI =
“N0000006373”] with preferred name “Famotidine
[Chemical/Ingredient]”. We grouped this concept into
“Chemical/Ingredient” category. Taking the same process
as we did for SPL, we searched the RXNSAT table for a
list of setIds with a given RxCUI and established linkages
between NDF-RT and SPL. Figure 7 show the workflow of
the data extraction in this step.
Results
EPC indexing SPL, NDF-RT and RxNorm were used for
profiling SPL drug labels with detailed category and
standardized drug information. We presented the outcomes
from each resource below.
Figure 6 Data extraction workflow for RxNorm and
SPL mappings.
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The mapping results based on EPC indexing SPL labels are
listed in Table 2. In total, 354 EPC unique classes were
identified from the EPC indexing SPL labels, which link to
853 unique SPLs. In the meantime, we extracted all individ-
ual NDF-RT concepts with NUIs that are mapped to their
corresponding EPC classes via different role relationships.
154 NDF-RT concepts were mapped to EPC classes via the
role relationship “has_Chemical_Structure”, 70 concepts via
“has_PE” and 7 concepts via “has_MoA”. The coverage of
NDF-RT and SPL for each category are calculated and
shown in Table 2. Here, the coverage for NDF-RT is calcu-
lated by the number of NDF-RT concepts in each category
divided by the total number of NDF-RT concepts (47,075
in total), and the coverage for SPL was calculated by the
number of SPL labels in each category divided by the total
number of SPL labels (36,568 in total). There are totallyFigure 7 Data extraction workflow for NDF-RT and
SPL mappings.497 EPC classes identified from the NDF-RT RDF reposi-
tory, indicating that 71.2% (354 out of 497) EPC classes
have been integrated into the EPC Indexing SPL labels.
Results from RxNorm vs. NDF-RT mappings
We executed SQL queries and extracted 41,343 unique
RxNorm entries (RxCUI) with NUIs and preferred names
from RxNorm and NDF-RT mappings. To make linkages
between SPL and NDF-RT, we searched each given RxCUI
for a set of setIds from RXNSAT table. Finally, of 9,053
unique NUIs with setId, 6,611 unique NUIs belonging to
three NDF-RT categories - “VA Product”, “Chemical/
Ingredient”, and “EPC” are associated with 35,094 unique
SPL setIds. In this step, we utilized NDF-RT category
information to profile SPL.
The mapping results from RxNorm and NDF-RT
mappings are listed in Table 3. There are 4,880 unique
NDF-RT concepts from the category “VA Products”, linking
to 20,937 unique SPL labels; whereas there are 1,730
unique chemical ingredients linking to 34,788 SPL labels.
Comparing with the above EPC class mapping, only one
EPC class identified and linked to 14 SPL labels have been
integrated into RxNorm. The coverage is calculated by the
number of concepts within each category divided by 47,075
NDF-RT concepts / 36,568 SPL labels. 96% SPLs have been
covered by the RxNorm and NDF-RT mappings, whereas
only 14.0% NDF-RT concepts have been linked to the SPL
labels.
Total 20,631 SPL labels have been mapped to more than
one category. As an illustration, one SPL label “Cavan-EC
SOD DHA” (setId = “0f2053f1-fd94-4a4a-b803-bca391d
9e032”) has been mapped to “Fatty Acids, Omega-3
[Chemical/Ingredient]” (NUI = “N0000006244”), “SILICON
DIOXIDE [VA Product]” (NUI = “N000158434”) and
“Omega-3 Fatty Acid [EPC]” (NUI = “N0000175583”). In
the meantime, there are 2,442 unique NUIs without
category information, but they are duplicated with other
concepts from the three categories. For example, “Mesna”
(NUI=“N0000147595”) without category information has
child concepts “MESNA 100MG/ML INJ” (NUI=“N0000
156948”) assigned to “VA Product”. For this case, we did
not count “Mesna” as a “VA Product”. However, we under-
stand that “Mesna” is a drug class used to categorize its
subclasses informed by “VA Product”.
Results from RxNorm vs. SPL mappings
We first identified 35,480 unique SPL entries from RxNorm
and SPL mappings with “SAB= MTHSPL”. And then we
identified 15,615 unique RxCUIs that correspond to the
SPL setIds by searching RXNSAT MySQL table. We used
the term types “TTY” to classify SPL labels into ten
categories. Each category with the number of unique
RxCUIs, unique setIds and their coverage has been listed in
the Table 4. Comparing with the 36,568 SPL labels from
Table 2 Mapping results by EPC classes based on EPC Indexing SPL Labels
Category Num. of unique NUIs NDF-RT Coverage by EPC Num. of unique setIds SPL Coverage by EPC
EPC 354 0.8% 853 2.3%
Chemical/Ingredient 154 0.3% 342 0.9%
PE 70 0.2% 201 0.6%
MoA 7 0.01% 10 0.03%
Total 585 1.2% 858 2.4%
“Category” denotes NDF-RT categories extracted from EPC indexing SPL;
“NUI” denotes identifier of NDF-RT;
“setId” denotes identifier of SPL.
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97.0% SPLs have been covered by RxNorm and SPL
mappings, whereas only 1.6% RxNorm has been linked to
the SPL labels.
It is worthy to note that there are overlaps among
concepts with different TTYs, such as SY and TMSY that
denote synonyms of another TTY, thus concepts with SY
or TMSY are overlapping with concepts with other TTYs.
Also the same as RxNorm and NDF-RT mappings, there
are overlaps for SPL labels among all of the categories.
Network visualization
The profiling results of SPL drug labels using RxNorm and
NDF-RT not only demonstrate the connections among
these three resources, but also help establish a drug/drug
class network based on them. Within this network, the
target and source nodes represent the concepts from SPLs,
RxNorm or NDF-RT; the edges represent the category
information. We are exploring Cytoscape [20] as a
visualization tool to display and analyze the network.
Figure 8 displays the network constructed using the results
from this study. The upper right picture in Figure 8 shows
a subset of the entire network; and the lower right picture
shows one of the sub-networks with NDF-RT concepts as
source nodes, SPL labels as target nodes, and category EPC
as edge; and the details about nodes are shown in the lower
left picture in Figure 8.
Discussion
SPL labels contain a large portion of clinical drugs, and
chemical/ingredients, as well as other possible drug
categories. SPL labels as a very useful drug knowledge
resource have been applied in clinical drug applicationsTable 3 Mapping results by RxNorm/NDF-RT mappings





“Category”: NDF-RT categories from NDF-RT/RxNorm mappings;
“NUI”: identifier of NDF-RT;
“setId”: identifier of SPL.such as Adverse Drug Events (ADEs) detection from elec-
tronic medical records (EMRs). Notably, a number of stud-
ies are emerging recently to use the SPL labels for the
purpose of drug safety surveillance. For example, in a
project called SIDER, a public, computer-readable side
effect resource that connects 888 drugs to 1450 side effect
terms was developed using the SPL labels [21]. In a system
called ADESSA, as another example, the ADEs were
extracted from the SPL labels and mapped to the MedDRA
terms and concepts, then utilized the UMLS to generate
mappings between the MedDRA terms and the SNOMED
CT concepts [22]. In a project at Mayo Clinic, the SPL
labels were used in a framework for building a standardized
ADE knowledge base known as ADEpedia [23] through
combining ontology-based approaches with Semantic Web
technology. In addition, Schadow conducted some other
studies to evaluate the impact of SPL for medication know-
ledge management [24]. And Schadow also had successfully
aligned SPL with associated terminologies to make drug-
intolerance (allergy) decision support in computerized
provider order entry (CPOE) systems in 2008 [25].
In this paper, we have successfully mapped SPL labels to
NDF-RT and RxNorm, and categorized them using drug
class information and clinical drug identification informa-
tion respectively. 96.0% of SPL drug labels are mapped with
NDF-RT categories whereas 97.0% of SPL drug labels are
linked to RxNorm codes. The high SPL coverage by NDF-
RT and RxNorm indicates that, on the one hand, the two
drug ontologies are the appropriate data standards for
normalizing drug information covered by SPL drug labels.
On the other hand, the knowledge structure asserted in the
two drug ontologies can be leveraged to analyze and enrich





Table 4 Mapping results from RxNorm and SPL mappings
TTY Num. of unique RxCUIs Coverage by RxNorm Num. of unique setIds Coverage by SPL
SBD 6714 0.70% 7087 19.38%
SCD 5981 0.6% 21127 21.9%
IN 1,834 0.2% 34,038 93.1%
PIN 773 0.08% 18,498 50.6%
BPCK 261 0.03% 259 0.7%
GPCK 48 0.005% 150 0.04%
BN 2 0.0002% 5 0.01%
MIN 2 0.0002% 3 0.008%
SY* 11,489 1.2% 21,438 58.6%
TMSY* 1,810 0.2% 4,208 11.5%
Total 15,615 1.6% 35,480 97.0%
“TTY” denotes term types from RxNorm;
“RxCUI” denotes identifier of RxNorm;
“setId” denotes identifier of SPL.
“*” denotes the concepts with SY and TMSY have overlaps with the concepts in other TTYs.
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to indicate the role an atom plays in its source (see Table 1)
and specifies the relationships between the term types (see
Figure 2). We utilized the term types to profile the SPL
drug labels, which resulted in very useful insights on the
characteristics of the existing SPL drug labels as an import-
ant drug knowledge source. We found that the majority of
SPL drug labels (93.1%, see Table 4) are linked with the
RxNorm term type “IN” which is defined as a compoundFigure 8 Network visualization of a drug and drug class network bas
the subsets of entire drug network built using the results from this st
lower left illustrates the details about the sub-network shown in loweor moiety that gives the drug its distinctive clinical proper-
ties. Only 21.9% of SPL drug labels are linked with the
RxNorm term type “SCD” which is defined as the semantic
clinical drugs with the combination of “Ingredient
+ Strength + Dose Form”. These findings indicate that
when the SPL drug labels are utilized for a clinical drug
application, the mappings through the ingredients would
provide a better coverage (i.e., more sensitive) than through
the combination of “Ingredient + Strength + Dose Form”.ed on the profiling results of SPL drug labels (The upper left is
udy; the lower right is an enlarged subset of the network; the
r right).
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linked with the term type “SCD” through asserted relation-
ships (see Figure 2). This provides additional options to
optimizing the use of SPL drug labels in a clinical drug
application through RxNorm.
Similarly, there is a content model asserted for modeling
knowledge structure of NDF-RT (see Figure 1). We utilized
the categorical drug class in the NDF-RT to classify the
SPL drug labels. Our finding indicates that 95.1% of SPL
drug labels are classified into the category “Chemical/
Ingredient” and 57.3% of SPL drug labels are classified into
the category “VA Product” which is analogous to the
clinical drugs. While the finding from NDF-RT is consist-
ent with what we have found in the RxNorm, NDF-RT
provides more powerful analysis and aggregation capability
because it contains a hierarchical concept structure that
defines a rich set of domain-specific categories. For
example, when a clinical application needs to collect drug
information for all cardiovascular medications, NDF-
RT provides a category “[CV000] CARDIOVASCULAR
MEDICATIONS” which contains 16 direct subcategories
and 1246 descendant classes in total (from NDF-RT version
2012.02.06). Using the asserted knowledge, the SPL drug
labels that have been classified into the category “VA
Product” will be able to aggregate to various domain-
specific categories based on the requirements of a clinical
application. This is also an important area we will explore
in the future.
A drug and drug class network was built based on the
SPL mappings with different data resources: EPC classes,
NDF-RT and RxNorm. From such network, it can allow us
to explore more drug class information for SPL drug labels
and their connections with other clinical drugs. We are
exploring Cytoscape [20] as a visualization tool to display
and analyse the network. We consider that this is an
important module of the system because it will provide a
user friendly interface to allow end users to capture their
target information efficiently. Note that we only integrated
drug information into this network; we will integrate more
drug / drug class resources, like PharmGKB [26], DrugBank
[29], or National Drug Code (NDC) [27] into this network.
In addition, the drug related phenotype information inte-
gration will be the next target in our future study. These
integration efforts will make the network more useful to
support clinical applications such as a clinical decision
support system for clinicians.
Semantic Web technologies are being widely used in the
biomedical research field. For instance, a well-known
Linked Data application known as Bio2RDF [28] provides
interlinked life science data to support biological knowledge
discovery. It seamlessly integrates about fifty machine inter-
pretable data to support federated queries for complex
questions. LinkedSPLs [2], another SPL centred Linked
Data resource, links SPL to DrugBank [29], ChEBI [30],etc., and makes both the original and extracted product
label contents queriable using drug identifiers presented in
these drug information resources. Although these Linked
Data applications are focusing on data integration, none of
them takes further steps to organize product labels from
the perspective of drug class and clinical drug identification.
In the present study, we applied EPC classes, NDF-RT and
RxNorm to standardize and categorize SPL labels into
different drug classes, aiming at integrating them into a
standard drug / drug class network.
Semantic Web technology plays a key role in the imple-
mentation of our system. We represented the drug data
from NDF-RT and SPL drug labels in RDF triples and
hosted the RDF triples in a RDF triple store. We consider
this makes the data integration, data management more
feasible. In addition, running SPARQL queries against RDF
store through SPARQL endpoint simplified our efforts on
linking SPL drug labels to NDF-RT by using the predicates
defined in the RDF triples. The NLM has not provided
RDF based data format for RxNorm. In this study, we
stored and analyzed the RxNorm data based on a relational
database. In the future study, we will employ D2R [31]
server for the RxNorm RDF transformation through defin-
ing mappings between the RRF-based relational database
schema and a RDF data model, and also explore an
RxNorm SPARQL endpoint offered recently by the NCBO
BioPortal and integrate the RxNorm into the Semantic
Web based framework of our system.
Conclusions
In this study, we have successfully mapped SPL drug labels
with RxNorm and NDF-RT. In total, 96.0% of SPL drug
labels are mapped with NDF-RT categories whereas 97.0%
of SPL drug labels are linked to RxNorm codes. We found
that the majority of SPL drug labels are mapped to chemical
ingredient concepts in both drug ontologies whereas a rela-
tively small portion of SPL drug labels are mapped to clinical
drug concepts. We believe the profiling outcomes produced
by the study would provide useful insights on meaningful
use of FDA SPL drug labels in clinical applications through
standard drug ontologies such as NDF-RTand RxNorm.
We will continue the following investigations in the
future. 1) Since existing SPL drug labels have been classified
into a number of categories, including over-the-counter
(OTC), prescription, animal, and so on, we will explore to
integrate the information into the current drug network; 2)
we will build a backbone drug network based on NDF-RT
and integrate the network with more drug resources such as
DrugBank, NDC, PharmGKB, etc.; 3) we will explore to
build linkages between the drug/drug class and relevant
phenotype/genotype.
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